Intraoperative "p50" Measurement in Liver Transplant Surgeries

NCT ID: NCT06660095

Last Updated: 2024-10-26

Basic Information

• Recruitment Status: ENROLLING_BY_INVITATION
• Total Enrollment: 25 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2024-10-22
• Study Completion Date: 2025-01-21

Brief Summary

The aim of this study is to compare the p50 value in routine blood gas measurements taken during liver transplant surgery follow-up with other follow-up parameters and clinical findings on the monitors, and to investigate whether there is a predictive parameter that can predict the rapidly changing clinical findings of the patients.

Detailed Description

Blood gas monitoring is the most commonly method used by anesthetists during liver transplant surgeries. We evaluated the blood gas p50 value according to the stages in these heart transplant operations. We tried to find out how the blood gas p50 value would guide the patient's clinical findings in the dissection phase, anhepatic phase and neohepatic phase. For this purpose, we compared arterial and venous blood gas p50 values with the patient's vital signs at certain stages in liver transplant surgeries.

Conditions

Liver Transplant; Complications

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: PROSPECTIVE

Study Groups

Liver transplant recipients

T0: After the anesthesia induction, before the surgery T1: Intraoperative p50 value from the blood gas sample taken during the dissection stage T2: Intraoperative p50 value from the blood gas sample taken during the anhepatic stage T3: Intraoperative p50 value from the blood gas sample taken during the neohepatic stage T4: After the hepatic artery reperfusion T5: At the end of the surgery

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Liver transplant recipients who will undergo Elective Liver Transplant surgery at İnönü University Faculty of Medicine Liver Transplant Institute, ASA (American Society of Anesthesiology) score III-IV, patients between the ages of 18-65

Exclusion Criteria

• Patients with fulminant liver failure,
• hepatic encephalopathy,
• hepatorenal,
• hepatopulmonary syndrome,
• uncontrolled diabetes mellitus,
• cardiovascular, pulmonary disease,
• sepsis
• and patients who refuse consent in the informed consent form will be excluded from the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Inonu University

OTHER

Sponsor Role: lead

Responsible Party

Yusuf Ziya ÇOLAK

Assoc. Prof. Muharrem Ucar, MD.

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Muharrem UCAR, assoc.Prof.

Role: STUDY_DIRECTOR

Inonu University

Locations

İnönü Üniversitesi Merkez Kampüsü (Elazığ Yolu 15.km) Battalgazi

Malatya, , Turkey (Türkiye)

Countries

Turkey (Türkiye)

References

Kim Y, Jung JH, Kim GE, Park M, Lee M, Kim SY, Kim MJ, Kim YH, Kim KW, Sohn MH. P50 implies adverse clinical outcomes in pediatric acute respiratory distress syndrome by reflecting extrapulmonary organ dysfunction. Sci Rep. 2022 Aug 11;12(1):13666. doi: 10.1038/s41598-022-18038-6.

Reference Type: RESULT

PMID: 35953629 (View on PubMed)

Hall TH, Dhir A. Anesthesia for liver transplantation. Semin Cardiothorac Vasc Anesth. 2013 Sep;17(3):180-94. doi: 10.1177/1089253213481115. Epub 2013 Mar 12.

Reference Type: RESULT

PMID: 23482506 (View on PubMed)

Other Identifiers

Inonu p50

Identifier Type: -

Identifier Source: org_study_id